Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation [7]

Leukemia

Volumn 20, Issue 7, 2006, Pages 1300-1303

  Haralambieva, Eugenia ^a   Adam, P ^a   Ventura, R ^b   Katzenberger, T ^a   Kalla, J ^a   Holler S ^a   Hartmann, M ^a   Rosenwald, A ^a   Greiner, A ^a   Muller Hermelink H K ^a   Banham, A H ^b   Ott, G ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG;

ADULT; AGED; B CELL LYMPHOMA; CANCER STAGING; CHROMOSOME BREAKAGE; CHROMOSOME MAP; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR LOCALIZATION;

EID: 33745194641     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404244     Document Type: Letter

References (8)

1. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 2005; 19: 652-658.
2. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299-1305.
3. Fenton JA, Schuuring E, Barrans SL, Banham AH, Rollinson SJ, Morgan GJ et al. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2005; 45: 164-168.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001.
5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
6. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065-1072.
7. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933-2935.
8. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183-3190.